TIL Instil Bio, Inc. Stock Quote

TIL [NASD]

Index	-	P/E	-	EPS (ttm)	-1.46	Insider Own	2.45%	Shs Outstand	129.12M	Perf Week	1.70%
Market Cap	639.85M	Forward P/E	-	EPS next Y	-1.91	Insider Trans	0.00%	Shs Float	126.13M	Perf Month	-39.72%
Income	-187.80M	PEG	-	EPS next Q	-0.41	Inst Own	91.80%	Short Float	7.03%	Perf Quarter	-56.66%
Sales	-	P/S	-	EPS this Y	-393.20%	Inst Trans	1.61%	Short Ratio	14.23	Perf Half Y	-70.69%
Book/sh	3.94	P/B	1.21	EPS next Y	-21.20%	ROA	-30.10%	Target Price	24.75	Perf Year	-75.09%
Cash/sh	2.84	P/C	1.69	EPS next 5Y	-	ROE	-32.60%	52W Range	3.90 - 23.68	Perf YTD	-72.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-79.81%	Beta	-
Dividend %	-	Quick Ratio	10.60	Sales past 5Y	-	Gross Margin	-	52W Low	22.56%	ATR	0.62
Employees	412	Current Ratio	10.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.61	Volatility	9.96% 13.71%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-133.30%	Profit Margin	-	Rel Volume	1.11	Prev Close	4.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	622.84K	Price	4.78
Recom	1.70	SMA20	-11.22%	SMA50	-28.42%	SMA200	-64.43%	Volume	688,083	Change	-1.04%

Aug-13-21

Initiated

Robert W. Baird

Outperform

$34

Apr-13-21

Initiated

Truist

Buy

$32

Apr-13-21

Initiated

Morgan Stanley

Equal-Weight

$24

Apr-13-21

Initiated

Cowen

Outperform

May-27-22 07:00AM	Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment GlobeNewswire -24.34%
May-18-22 07:00AM	Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire -5.09%
May-16-22 07:00AM	Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire +8.70%
Mar-07-22 07:00AM	Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Mar-02-22 07:00AM	Instil Bio to Present at the Cowen 42nd Annual Health Care Conference GlobeNewswire
Nov-15-21 07:00AM	Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
07:00AM	Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-10-21 11:28AM	Was The Smart Money Right About Instil Bio, Inc. (TIL)? Insider Monkey
Nov-08-21 08:05AM	Instil Bio to Present at Upcoming Investor Conferences in November GlobeNewswire
Sep-16-21 07:00AM	Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress GlobeNewswire
Sep-15-21 04:27PM	Why Iovance Is Up Nearly 11% Today Motley Fool +16.55%
Sep-13-21 07:00AM	Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma GlobeNewswire
Sep-02-21 07:00AM	Instil Bio to Present at Upcoming Investor Conferences in September GlobeNewswire +7.49%
Aug-12-21 07:00AM	Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-19-21 02:34PM	Do Hedge Funds Love Instil Bio, Inc. (TIL)? Insider Monkey
Jun-21-21 10:06AM	Are Institutions Heavily Invested In Instil Bio, Inc.'s (NASDAQ:TIL) Shares? Simply Wall St.
Jun-01-21 07:00AM	Instil Bio to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-13-21 07:00AM	Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire +5.83%
Apr-29-21 08:45AM	At a Recent Cancer Research Conference, Instil Bio Stole the Show Motley Fool +6.10%
Apr-27-21 07:00AM	Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma GlobeNewswire
Apr-12-21 07:18AM	Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-23-21 05:00PM	Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading Barrons.com
Mar-18-21 08:26PM	Instil Bio Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience